miR-34a repression of SIRT1 regulates apoptosis

By M. Yamakuchi, M. Ferlito, C. Lowenstein. Proceedings of the National Academy of Sciences of the United States of America, 2008

1,349 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/7c6287f39dd64dc34794e3ac55475c64ed3246e5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. A. Bader
2. Danish H Sayed
3. Carol Prives
4. Karen H. Vousden
5. M. Jansson
6. A. Lund
7. M. Abdellatif
8. Frank J. Slack

In Molecular Biology

1. A. Bader
2. Carol Prives
3. Karen H. Vousden
4. R. Houtkooper
5. Danish H Sayed
6. Johan Auwerx
7. M. Jansson
8. A. Lund

Citations in the corpus

• Sirtuins as regulators of metabolism and healthspan (2012, background): “As such, mouse miR-34a represses SIRT1 expression following genotoxic stres”
• MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells (2009, neutral): “Recently, the three members of the miR-34 family were found to be directly regulated by p53 and the functional activity of miR-34 indicated a potential role as a tumor suppressor [6,7,8,9,10,11,12].”
• Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer (2017, background): “miR-34a SIRT1, FMNL2 and E2F5 Inhibition and induction of p53 acetylation [53,54]”
• Blinded by the Light: The Growing Complexity of p53. (2009, background): “More recently, the sirtuin SIRT1 was also shown to be a target of miR-34a, and its downregulation correlates with increased acetylation of p53 (Yamakuchi et al., 2008).”
• MicroRNAs in development and disease. (2011, background): “Also, by targeting and suppressing Sirt1, it increases acetylation and activation of p53, and thereby induces apoptosis in p53-positive CRC cells (683).”
• Age Related Changes in NAD+ Metabolism Oxidative Stress and Sirt1 Activity in Wistar Rats (2011, neutral): “[73].”
• miR-34 – a microRNA replacement therapy is headed to the clinic (2012, background): “…feedbackloop by targeting SIRT1 (silent information regulator 1), a NAD-dependent deacetylase that deactivates TP53 (tumor protein 53), and YY1 (yin yang 1), a protein that binds to p53 and promotes p53 ubiquitination and degradation (Sui et al., 2004; Yamakuchi et al., 2008; Chen et al., 2010).”
• Identification of miR-34a as a potent inhibitor of prostate cancer progenitor cells and metastasis by directly repressing CD44 (2011, positive): “Cyclin D1, CDK4 and 6, E2F3, N-Myc, c-MET and BCL-2 have been reported to be direct targets of miR-34”